ClinicalTrials.gg
Status unknownNCT02940210Updated Oct 20, 2016

Clinical Trial to Evaluate the Efficacy and Safety of Adhesion Barrier Mediclore Versus no Treatment in Patients With Total Thyroidectomy

A Phase 3 interventional study of Mediclore® (adhesion barrier) in Patients With Thyroidectomy (Scheduled), sponsored by CGBio Inc.. Status unknown at 1 site in Korea, Republic of. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2016-10-20.

Sponsored by CGBio Inc. · Phase 3, Interventional, and Prevention

The sponsor has not verified this record recently (last verified Oct 2016), so the status shown — last known as Recruiting — may be out of date.
Phase
Phase 3
Study type
Interventional
Enrollment
172
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Study summary

A randomized, single-blind, multi-center, Phase III clinical trial to evaluate the efficacy and safety of adhesion barrier Mediclore versus no treatment in patients with total thyroidectomy

02

Conditions studied

  • Patients With Thyroidectomy (Scheduled)
03

In context

Lead sponsor

CGBio Inc. is the lead sponsor of 7 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written
  • Male or female at least 20 years of age
  • Patients without lab
  • Patients scheduled for thyroidectomy

Exclusion criteria

Exclusion Criteria:

  • Another clinical trials within 1 month
  • History of previous surgery on same position
  • Anticoagulant, general within a week from surgery
  • or disease
  • General or local infection
  • Serious diseases (heart failure, renal failure, liver failure, uncontrolled hypertension, diabetes mellitus, coagulation deficiencies)
  • Incompatible medications
  • History of drug or alcohol abuse, mental disorder
  • Pregnant or lactating women and fertile women who is not using proper method
  • History of esophagus diseases
  • Keloid symptoms
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
172 participants (estimated)

Study arms

  • Experimental
    Mediclore®

    adhesion barrier Mediclore 5cc, to apply medical device fully around thyroid gland following thyroidectomy

    Device: Mediclore® (adhesion barrier)

  • No intervention
    No treatment

    No treatment, standard treatment for thyroidectomy

Interventions

  • DeviceMediclore® (adhesion barrier)
06

What researchers measure

Primary outcomes

  1. Adhesion incidence rate following 8 weeks

    Time frame: 8 weeks

07

Study locations

1 of 1 sites recruiting
  • Ajou University Hospital
    Su won, Gyeonggi-do, Korea, Republic of
    Recruiting
    • Ha Eun Lee · Contact+82-31-219-4536
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2016 and a primary completion of Mar 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 19, 2016
First posted
Oct 20, 2016
Start
Aug 2016
Primary completionEst.
Mar 2017
Last update
Oct 20, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 20, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02940210
Lead sponsor
CGBio Inc.
Responsible party
Sponsor
First posted
Oct 20, 2016
Start date
Aug 2016
Primary completion
Mar 2017 (estimated)
Last update
Oct 20, 2016

Study contacts

Wan Huh
Contact
whuh408@daewoong.co.kr
+82-2-550-8106

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion